NRS Offers Health Agencies Access to Its Digital Advertising Network to Provide Critical Public Health Updates During the Covid-19 Crisis

Newark, NJ, March 14, 2020 -- National Retail Solutions (NRS), the operator of a leading nationwide point-of-sale (POS) network for independent retailers, announced that it is offering public health agencies complimentary access to its digital out-of-home (DOOH) advertising network to disseminate critical public health announcements during the Covid-19 outbreak.

“Our retailer partners are concerned by the potential of the Covid-19 outbreak to impact their businesses. However, they are even more worried by what the virus may mean to the health of their customers and their families,” said Elie Y Katz, President of NRS. “To support these independent retailers and the urban communities they serve across the country, we are offering governmental public health agencies the ability to display PSAs free of charge on the 8,000 plus screens of our NRS Digital Media Impact Network to share critical public health information, updates and advisories.”

Eli Korn, COO of NRS, explained, “The majority of our retail partners serve multicultural, immigrant-dense metropolitan areas across the U.S. These are among the most hard-to-reach and culturally diverse communities in the country. Within these communities, bodegas and independent neighborhood convenience stores often serve as informal community centers where customers share news and information. We invite governmental public health agencies to utilize our digital display network to help keep these communities advised of evolving public health advisories and critical healthcare and safety information.”

The NRS Digital Media’s Impact Network reaches approximately 35 million people per month, predominantly in the nation’s urban centers. The Impact Network’s display screens are located at eye-level at the point of sale in 8,000+ independent convenience, grocery, liquor and tobacco stores nationwide. Unlike most conventional advertising venues, NRS has the ability to provide updated content on demand through its Impact Network as new health information becomes available.

NRS can run 8-10 second static or video advertising as part of a 60-second loop. PSAs and advertisements can be run in any language, and NRS can provide agencies with information on language and demographics regionally and for specific stores. Advertising is visual only (without sound).

NRS is offering this public service to governmental public health agencies for the remainder of the month of March 2020 and may extend the offer at its discretion as conditions warrant. This offer is contingent upon, and subject to, limitations based on network capacity, appropriate volumes, and content at the sole discretion of NRS.

Agencies interested in participating should contact Leslie Ruder at This email address is being protected from spambots. You need JavaScript enabled to view it., call 973.438.5731 or inquire via nrsadvertising.com.

About National Retail Solutions (NRS):
NRS operates a point-of-sale (POS) terminal-based platform plus NRS PAY credit card processing for independent retailers and bodega owners nationwide. The platform provides a robust portfolio of tools to help these retailers compete more effectively, including inventory tracking, store statistics, user management, one-touch Boss Revolution® PIN-less recharge, and integration with the BR Club customer loyalty program. Consumer packaged goods (CPG) suppliers are able to leverage the NRS platform to provision promotions, coupons and special offers to independent retailers and their predominantly urban customer bases nationwide. NRS is a subsidiary of IDT Corporation (NYSE: IDT).

Media Contact:
Elie Y. Katz
Founder & CEO / National Retail Solutions (NRS)
201-715-5179

Preventive Measures from Coronavirus

Coronavirus threatening spread in India, here's how you can keep yourself safe from the plague.

As of now, a vaccine has not been invented for the coronavirus. For a fact, prevention appears to be the best cure available so far.

Here are some  measures you need to take:

1.

Avoid any close contact with a person who is ill. Keep at least three feet of distance between yourself and a person who is sneezing or coughing. 

2.

Avoid touching your mouth, nose, and eyes.

3.

Stay at home when you feel sick.

4.

Cover your mouth while coughing or sneezing with a tissue, then dispose of the tissue safely.

5.

Disinfect and clean regularly-touched objects and things using a regular household cleaning spray or wipe.

6.

Applying a mask is not compulsory unless you are taking care of an affected person. The Centers for Disease 52 Control does recommend that only infected persons wear masks to prevent the spread of the plague.

7.

Wash your hands often with water and soap for more than 20 seconds, mostly after going to the washroom, before eating, and after blowing your nose, coughing, or sneezing.

8.

If soap and water are not available, use an alcohol-based hand sanitizer with at least 60 percent alcohol. Always wash hands with soap and water when hands are dirty.

9.

If you have a fever, cough and difficulty breathing, seek medical attention immediately.

10.

Keep in mind the travel China/13 advisory set out by the Ministry of Health and Welfare.

Source:    : https://latestnewssuno.com/news/Health/Health/Preventive-Measures-from-Coronavirus/122

Dubai Congress Ambassador Award Event, JAFZA, March 2, 2020, Dubai.

Dubai, United Arab Emirates., March 10, 2020 -- Dr. Mahaveer Mehta Medical Center was awarded the Dubai Congress Ambassador Award by Director General of Dubai Tourism H.E.Helal Saeed Almarri and Dubai Tourism CEO Issam Kazim at an event organized by the Dubai Tourism Department.

The Medical Center received this token of appreciation for bidding and organizing successful international Dermatology conferences in Dubai, UAE.

The event was held at the JAFZA Convention Center in Dubai on March 2, 2020.

This prestigious event was attended by government officials from various departments in Dubai.

"This is the second time we are receiving this award. We bagged the first one in 2016, and now after 4 years we are receiving the Ambassador award by Dubai Tourism once again. I'm grateful to the government of Dubai for honoring us. This is huge moment and we are delighted. It will motivate me and my team to continue to provide highest standard of healthcare, and to grow the medical tourism in Dubai further," said Dr. Mehta.

About Dr. Mahaveer Mehta:
Dr. Mehta has been successfully running his medical center for the last 30 years in UAE and has treated over 150 nationalities, many of which travel for his treatment to Dubai. He is also a recipient of several other international awards such as 'Outstanding Contribution for International Mentorship' from American Society of Dermatological Surgery and many more. An invited speaker in several countries, he has over 15 research publications in various International Dermatology Journals. He can be contacted via email This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information please visit www.skinlaserdubai.com

Contact:
Dr. Mahaveer Mehta
Dr. Mahaveer Mehta Medical Center
641-B, Alghurair center
P O Box 14477
Dubai, United Arab Emirates
97150-4561999
This email address is being protected from spambots. You need JavaScript enabled to view it.
http://www.skinlaserdubai.com

Sensabues breath collection technology integrated into RCU Labs’ Test to determine recent cannabis use.

Stockholm, Sweden and Roseville, California, USA., March 6, 2020 -- Sensabues AB (“Sensabues”), a leading provider of breath collection technology for detection of drugs, doping and diseases, today announced that it has partnered with RCU Labs, Inc. (“RCU Labs”), a leader in the development of a dual-matrix test for recent cannabis use.

The partnership will see Sensabues and RCU Labs combine their respective technologies to launch the first accurate Recent Cannabis Use Test (“RCU Test”) using breath collection. The new test solves one of the most scientifically elusive issues of the cannabis industry: how to determine whether an impaired driver or employee is under the influence of cannabis.

The RCU Test is the first reliable test method to accurately determine recent cannabis use within the impairment window. The RCU Test is a practical alternative to zero-tolerance and arbitrary tetrahydrocannabinol (THC) drug level policies.

Method

RCU Labs has developed a new pharmacological testing approach based on multiple parameters involving key cannabinoids and Delta9-THC metabolites in blood. The results of the blood test are able to determine recent cannabis use within six hours. To enhance the confidence levels of the RCU Test, RCU Labs has incorporated a second test matrix, exhaled breath, utilizing the patented, low-cost breath collection device from Sensabues. The breath sample can be collected roadside or at an incident site, while the blood sample can be collected at the same time or, if required, up to several hours later. Both the breath and blood samples are then sent to the lab and analyzed using established instrumentation techniques such as high-resolution mass spectrometry for confirmatory data and evidential results. Overall, this dual-matrix approach yielded 100% accuracy within the impairment window following smoking in the first 44 consecutive subjects that have been studied in a clinical trial to date.

Applications

This collaboration seeks to advance the application breakthrough achieved by the RCU Test (patents pending) for law enforcement, workplace drug testing and anti-doping in sport with regard to ease of use and deployment in the field, as well as analytical accuracy in the lab. The RCU Test has obvious applications for law enforcement (roadside DUI collection), for employers investigating workplace incidents (with cause and post-accident situations) and for anti-doping in sport (in-competition testing of athletes and players).

Partnership

Under this agreement, both parties will work to offer a full suite of approved RCU all-in-one and one-time-use test kits together with the validated RCU analytical lab services. Further joint development of RCU Labs’ method is planned to extend the offering to include a definitive recent-use test for other drug groups such as stimulants and performance enhancing drugs.

Notes to Editors

More about Sensabues’ exhaled breath method:

Exhaled breath contains aerosols which originate from lungs and blood. These aerosols contain revealing information for diagnostics, therapeutics and analytics. Sensabues owns the core IP for the design of a simple collection device and the validated methodology to collect, extract and detect the non-volatile substances present within these aerosols using electrostatic filter technology.

This technique is convenient, reliable and low cost. It is a non-invasive way to collect chemicals in breath for disease detection, exposure monitoring, and drug metabolism.

This is a highly sensitive, accurate and confirmatory, back-to-lab based technique, which has been developed into a complete end-to-end analytical platform for use in toxicology, pharmacology and clinical biochemistry that can lead to improved analysis, diagnostics and therapies for medical research, healthcare, law enforcement, criminal justice, schools, workplace drug testing and sports organizations.

About Sensabues AB:
Sensabues is a Swedish company with exclusive ownership of a novel method and device to detect non-volatiles in breath. Over 20,000 breath collection devices have been deployed across targeted applications/markets worldwide. There are over 35 technical papers published with data from multiple worldwide studies and large scale field trials by independent third-party labs, institutes, hospitals, clinics, prisons, schools, and sports authorities. To date, over 80 different drugs and compounds have been detected across 25 different categories of substances using this method. www.sensabues.com

About RCU Labs, Inc.
RCU Labs, Inc., was founded by an established team of eminent scientists, with an extensive background in clinical pharmacology, toxicology and molecular medicine, with the aim of developing new testing approaches to address a number of currently pressing problems facing law enforcement, governing bodies, employers and employees worldwide. RCU Labs, headquartered in Roseville, CA, is accredited to the ISO/IEC 17025 international standard in chemical and forensic testing. The company currently has four patents pending that support the underlying technology behind the RCU Test. www.rculabs.com

Contact:
John Trainor
Sensabues AB
Humlegårdsgatan 4,114 46,
Stockholm, Sweden
+44 (0) 781 808 7755
This email address is being protected from spambots. You need JavaScript enabled to view it.
http://www.sensabues.com